91 results
S-8
EX-99.2
NGNE
Neurogene Inc
20 Feb 24
Registration of securities for employees
4:16pm
by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant’s short-term or long-term disability
8-K
EX-10.21
NGNE
Neurogene Inc
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
by a Participant (i) the Committee may determine that a leave of absence (including as a result of a Participant’s short-term or long-term disability
8-K
EX-10.6
yi6ah0
19 Dec 23
Neurogene Doses First Patients in Phase 1/2 Trial of NGN-401 for the Treatment of Female Pediatric Patients with Rett Syndrome
7:31am
425
sfnt c4i5f2a
4 Dec 23
Business combination disclosure
5:14pm
8-K
EX-10.1
no6zisscrrm0rpf3cht
4 Dec 23
Other Events
5:10pm
S-4/A
v0woaec
28 Sep 23
Registration of securities issued in business combination transactions (amended)
4:28pm
S-4
xhp3hdxfjb92oby8ns
18 Aug 23
Registration of securities issued in business combination transactions
6:19pm
425
nbyz tm9fzopbv
18 Jul 23
Business combination disclosure
4:02pm
425
6dxrxzm3
18 Jul 23
Business combination disclosure
8:37am
8-K
EX-2.1
tobmy1om 9ck4eg8a
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am
8-K
EX-10.1
sp4dh25zo8s9rdi
18 Jul 23
Neurogene and Neoleukin Announce Definitive Merger Agreement
8:34am